Navigation Links
Webcast Alert: Oscient Pharmaceuticals Announces Date for Release of Fourth Quarter Financial Results
Date:2/1/2008

WALTHAM, Mass., Feb. 1 /PRNewswire-FirstCall/ -- Oscient Pharmaceuticals Corporation (Nasdaq: OSCI) will release financial results for the fourth quarter and fiscal year ended December 31, 2007 on Wednesday, February 6, 2008 prior to the opening of the U.S. financial markets. A conference call will be held at 8:30 a.m. Eastern Time with Steven Rauscher, President and CEO, and other members of Oscient's management team. The Company announced preliminary revenue results of approximately $80 million for fiscal year 2007 on January 14, 2008.

What: Fourth Quarter and Fiscal Year 2007 Financial Results

When: February 6, 2008 at 8:30 am Eastern Time

How: Domestic participants can access the call by dialing

1-888-634-4009.

International participants are asked to dial 1-706-634-5451. The call

will also be webcast through the Company's website at

http://www.oscient.com.

Contact: Christopher Taylor, 781-398-2466 or Sarah Emond, 781-398-2544

A replay will be available two hours after the conclusion of the call until February 13, 2008. Domestic participants can access the replay by dialing 1-800-642-1687, while international participants are asked to dial 1-706-645-9291. The conference ID number for the replay is 33514080. A replay will also be available through http://www.oscient.com.

About Oscient Pharmaceuticals

Oscient Pharmaceuticals Corporation is a commercial-stage pharmaceutical company marketing two FDA-approved products in the United States; ANTARA(R) (fenofibrate) capsules, a cardiovascular product and FACTIVE(R) (gemifloxacin mesylate) tablets, a fluoroquinolone antibiotic. ANTARA is indicated for the adjunct treatment of hypercholesterolemia (high blood cholesterol) and hypertriglyceridemia (high triglycerides) in combination with diet. FACTIVE is approved for the treatment of acute bacterial exacerbations of chronic bronchitis and community-acquired pneumonia of mild to moderate severity. Oscient promotes ANTARA and FACTIVE through a nationwide sales force calling on primary care physicians, cardiologists, endocrinologists and pulmonologists. The Company also has a novel, late-stage antibiotic candidate, Ramoplanin, for the treatment of Clostridium difficile-associated disease (CDAD).

For important information regarding the safety and use of ANTARA and FACTIVE, please see the full prescribing information available at http://www.antararx.com and http://www.factive.com. For a complete description of the risks associated with our business please refer to the Company's Quarterly Report on Form 10-Q for the quarter ending September 30, 2007 and in other filings that we may make with the Securities and Exchange Commission from time to time.


'/>"/>
SOURCE Oscient Pharmaceuticals Corporation
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. 2008 Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference to Webcast Millennium Presentation
2. Webcast Alert: HCA Announces 4Q-Year End 07 Earnings Report
3. Kendle Invites You to Attend Its Fourth Quarter and Year End 2007 Earnings Conference Call and Webcast
4. CBIZ Webcasts Fourth-Quarter and Year-End 2007 Conference Call
5. RESMED to Webcast Second Quarter 2008 Earnings Conference Call
6. Coherent, Inc. to Webcast First Fiscal Quarter 2008 Results
7. Moog Inc. Announces First Quarter 2008 Earnings Webcast on January 25, 2008
8. BD Announces Webcast of Annual Meeting of Shareholders
9. PPD Announces Fourth Quarter and Year-End 2007 Earnings Release, Webcast and Conference Call
10. Zimmer Holdings Announces Webcast and Conference Call of Fourth Quarter and Full-Year 2007 Results
11. BD Announces Live Webcast of First Fiscal Quarter Earnings Conference Call
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2017)... ... February 27, 2017 , ... This ... laser diffraction analysis as a tool to characterize particle size distributions in the ... obtain improved results and novel scientific findings. It describes methods of optimized and ...
(Date:2/27/2017)... ... February 27, 2017 , ... Silicon Valley Hair Institute, a ... new informational post on robotic hair transplantation. San Francisco residents may be confused ... Follicular Unit Transplantation (FUT) can sound similar. Either treatment can be used to ...
(Date:2/26/2017)... ... February 26, 2017 , ... ... lab became the world’s first to be ISO/IEC 17025:2005 INAB accredited for Der ... , ISO/IEC 17025:2005 is the globally recognised standard that sets out requirements for ...
(Date:2/26/2017)... ARLINGTON, VA (PRWEB) , ... February 26, 2017 , ... ... Medicaid Managed Care Summit, February 27-28 at the Sheraton Pentagon City Hotel in Arlington, ... work with PerformCARE to use behavioral health analytics to improve Medicaid population health management. ...
(Date:2/24/2017)... ... February 24, 2017 , ... Houston dentist ... his office, Antoine Dental Center. Currently, patients can get single dental implants for ... but patients can learn more about these offers by contacting Antoine Dental Center. ...
Breaking Medicine News(10 mins):
(Date:2/27/2017)... Israel and TAMPA, Fla. , Feb. ... emerging medical device company focused on developing cerebral ... applauds the members of the FDA,s Circulatory System ... their acknowledgement of the need for cerebral protection ... "The statements shared by this FDA panel ...
(Date:2/27/2017)... Feb. 27, 2017  Impax Laboratories, Inc. (NASDAQ: IPXL ) today ... Raymond James and Associates, 38 th ... 2017 in Orlando, FL. Cowen ... ET on March 7, 2017 in Boston, MA. ... 16, 2017 in Miami, FL. ...
(Date:2/27/2017)... 27, 2017  CTI BioPharma Corp. (CTI BioPharma) (NASDAQ and ... , M.D., Ph.D., as President and Chief Executive Officer (CEO) ... 2017. Dr. Craig succeeds Richard Love , interim President ... Board of Directors.  Dr. Craig has over 20 years of ... US and Europe . "On ...
Breaking Medicine Technology: